Oric Pharma Reports Director Changes and Compensation Updates

Ticker: ORIC · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1796280

Oric Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyOric Pharmaceuticals, Inc. (ORIC)
Form Type8-K
Filed DateMar 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, compensation, governance

Related Tickers: ORIC

TL;DR

Oric Pharma shakes up board, adjusts exec pay. Big changes coming?

AI Summary

Oric Pharmaceuticals, Inc. announced on March 11, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of certain directors and the election of new ones, alongside updates to the compensatory arrangements for its officers. The filing also includes financial statements and exhibits.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board and executive changes, coupled with compensation adjustments, can introduce uncertainty about future strategic direction and operational stability.

Key Players & Entities

  • Oric Pharmaceuticals, Inc. (company) — Registrant
  • March 11, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080 (address) — Principal Executive Offices
  • (650) 388-5600 (phone_number) — Registrant's Telephone Number

FAQ

Who are the departing directors and who are the newly elected directors?

The filing indicates the departure of certain directors and the election of new ones, but does not specify their names in the provided text.

What specific changes were made to the compensatory arrangements of certain officers?

The filing states that there were updates to the compensatory arrangements of certain officers, but the specific details of these changes are not provided in the excerpt.

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported is dated March 11, 2025.

In which state was Oric Pharmaceuticals, Inc. incorporated?

Oric Pharmaceuticals, Inc. was incorporated in Delaware.

What is the principal executive office address for Oric Pharmaceuticals, Inc.?

The principal executive offices are located at 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding Oric Pharmaceuticals, Inc. (ORIC).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.